Reslizumab

What is Reslizumab

Reslizumab (Cinqair) is a humanized monoclonal antibody that targets interleukin 5, inhibiting its action.

The drug reduces eosinophil-meditated inflammation of the airways,

It is indicated for add-on maintenance treatment of adult patients with severe asthma with an eosinophilic phenotype. 

Brand Name

CINQAIR

Indications

  • asthma maintenance

For asthma maintenance add-on therapy in severe asthma (eosinophilic phenotype)

Side Effects

  1. antibody formation
  2. cough
  3. dizziness
  4. dyspnea
  5. fatigue
  6. headache
  7. hypotension
  8. muscle cramps
  9. musculoskeletal pain
  10. myalgia
  11. nasal congestion
  12. new primary malignancy
  13. pharyngitis
  14. rash
  15. serious hypersensitivity reactions or anaphylaxis
  16. sinusitis
  17. urticaria
  18. vomiting
  19. wheezing

Monitoring Parameters

  • laboratory monitoring not necessary
  • pulmonary function tests (PFTs)

Contraindications

  • acute bronchospasm
  • breast-feeding
  • children
  • corticosteroid withdrawal
  • deterioration of asthma
  • helminth infection
  • infants
  • neoplastic disease
  • new primary malignancy
  • pregnancy
  • requires a specialized care setting
  • requires an experienced clinician
  • serious hypersensitivity reactions or anaphylaxis
  • status asthmaticus

Interactions

There are no drug interactions associated with Reslizumab products.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top